Omkar Speciality Chemicals exits CIRP, posts FY26 losses

Exit from CIRP after NCLT approval

Omkar Speciality Chemicals Limited has officially transitioned out of the Corporate Insolvency Resolution Process (CIRP) after the National Company Law Tribunal (NCLT) approved its resolution plan on July 31, 2025. The approval sets the legal foundation for implementing a comprehensive restructuring of the company’s capital and ownership. CIRP for the Thane-based specialty chemicals manufacturer began on December 5, 2022 following loan defaults and a period of severe financial stress. The company’s estimated liquidation value during the process was ₹13.15 crore, underscoring the steep impairment that creditors and shareholders faced.

Post-approval, Omkar Speciality has been moving through the formal steps needed to implement the plan, including governance resets and procedural approvals. The company has also released unaudited financial results for the first three quarters of FY 2025-26, offering an early picture of operating conditions during the transition. The key takeaway from these numbers is stark: debt has been substantially addressed under the plan, but business operations have not yet restarted in a way that generates revenue.

What the NCLT order settled, and why it mattered

The NCLT Mumbai Bench, in an order involving Members Ashish Kalia (Judicial) and Sanjiv Dutt (Technical), approved the resolution plan submitted by Kshitij Polyline Limited. The tribunal dismissed objections raised by dissenting financial creditors Axis Bank Ltd. and NKGSB Co-operative Bank Ltd., which challenged the distribution approach for recovery proceeds. In its reasoning, the bench reinforced the primacy of the Committee of Creditors’ (CoC) commercial wisdom under Section 30(4) of the Insolvency and Bankruptcy Code (IBC).

A central point in the dispute was allocation based on security interest values. The order reiterated that a dissenting creditor cannot demand more than its liquidation value entitlement under the Code. This matters beyond this single case because it reinforces a framework where collateral value and priority can outweigh other arguments about distribution, particularly when the CoC has voted in favour of a plan. The resolution plan approval was backed by 83% of the CoC’s voting share, led by Bank of Baroda.

Resolution plan size and funding structure

The resolution framework approved for Omkar Speciality has been described in multiple figures within company and related disclosures. The plan was approved at ₹25.65 crore, alongside an overall infusion described as ₹26.65 crore in equity and loans. In crore terms, the overall package includes ₹4.75 crore of equity and ₹21.90 crore of loans, aggregating to ₹26.65 crore.

The plan’s payouts include ₹23.14 crore to creditors, with ₹21.76 crore going to secured lenders. Operational creditors are to be paid ₹0.064 crore (₹6.4 lakh), explicitly noted as above liquidation value. Alongside creditor settlements, the plan also provides for extinguishment of claims not included in the approved resolution framework, a standard but high-impact feature for legacy liabilities.

Capital restructuring: five steps and stock exchange approvals

A key part of the post-CIRP process is a five-step capital restructuring plan. It begins with a complete capital reduction to NIL, as per the NCLT order dated July 31, 2025. It then moves to a fresh equity issuance to the Resolution Applicant at a face value of ₹10, followed by the required in-principle approvals from stock exchanges. After share allotment, the Resolution Applicant is intended to hold 100% of the paid-up capital. Finally, the plan aims to meet minimum public shareholding norms through a 5% offer-for-sale (OFS) mechanism.

The company has indicated it will seek stock exchange approvals before implementing the share allotment process. For public shareholders, these steps are significant because they frame how and when the old capital base is extinguished and how the new shareholding structure is created.

Record date set for cancellation of existing shares

In line with the restructuring plan, Omkar Speciality’s monitoring committee convened on April 15, 2026 and set April 29, 2026 as the record date for extinguishment and cancellation of all existing equity shares. On that record date, all fully paid-up equity shares with a face value of ₹10 held by promoters, promoter group entities, and public shareholders are slated to be cancelled.

Simultaneously, the company is to issue 50 lakh new equity shares to IFFAS Kshitij SPV LLP at par value via private placement, raising ₹5 crore in cash. The stated outcome is a complete transfer of ownership, with IFFAS Kshitij SPV LLP becoming the 100% owner of Omkar Speciality Chemicals. The company has also referred to this as a precedent-setting post-CIRP capital overhaul, given the scale of share cancellation and re-issuance.

FY26 Q1 to Q3 results: revenue remains at zero

After the NCLT order, the company disclosed unaudited financial results for the quarters ended June 30, 2025, September 30, 2025, and December 31, 2025, corresponding to Q1, Q2, and Q3 of FY 2025-26. Across these three quarters, revenue from operations was reported as ₹0 crore.

Losses continued during the same period. The net profit or loss reported for FY26 Q1 to Q3 was a loss of ₹0.41 crore in Q1, a loss of ₹0.52 crore in Q2, and a loss of ₹0.33 crore in Q3. While the resolution plan is described as having substantially reduced debt, the financials highlight that operational revival is still a work in progress.

Auditor appointment and the going concern watchpoint

As part of the governance reset post-CIRP, Omkar Speciality appointed R. R. Tibrewala & Co. as statutory auditors for FY 2025-26. The company described this appointment as filling a casual vacancy and as part of formalising governance after the insolvency process.

The disclosures also reference an auditor’s qualified conclusion, particularly relating to the going concern basis in the context of negative net worth. For investors and creditors, this qualification is a practical signal that, even with a resolution plan approved, the company’s ability to sustain operations depends on executing the revival steps and restoring working operations. It also underscores why near-term financial statements are likely to remain focused on transition mechanics rather than growth.

Monitoring committee agenda: governance, management and funding

The monitoring committee has been central to implementing the plan and managing the transition. Omkar Speciality indicated that its monitoring committee would meet on May 27, 2026 to approve unaudited financials for the quarters ended June, September, and December 2025. Separately, the company also indicated that the monitoring committee approved unaudited financial results for Q1, Q2, and Q3 FY26 and made key appointments, including a new CEO, an independent director, and statutory auditors.

Beyond reporting and governance, the committee also approved a borrowing facility of up to ₹20 crore from Kshitij Polyline Limited, classified as non-convertible. The earnest money deposited by the successful resolution applicant before NCLT approval is to be recognised as part of the ₹21.90 crore funding package under the resolution plan. These steps tie directly to the stated need for capital expenditure and working capital initiatives, which the company has flagged as critical to reviving operations.

Market snapshot and what investors are tracking

Omkar Speciality Chemicals’ share price was reported at ₹3.6 as of June 4, 2026. While price levels alone do not explain fundamentals, the market context is shaped by three visible milestones: the July 31, 2025 NCLT approval, the April 29, 2026 record date for cancellation of existing shares, and the financing and governance steps being executed through the monitoring committee.

For existing shareholders, the record-date-driven cancellation and the issuance of new equity to the incoming entity are the most consequential elements. For lenders, the resolution plan’s payout structure and the NCLT’s reinforcement of security-interest-based distribution is a major legal and financial reference point.

Why the story matters for the specialty chemicals distress cycle

Omkar Speciality’s case combines three themes that often recur in distressed manufacturing turnarounds. First, legal closure through an approved plan can reduce debt and settle legacy claims, but it does not automatically restore operational revenue. Second, capital restructuring can be extreme, including cancellation of existing equity and transfer of ownership to a resolution applicant vehicle. Third, even with fresh funding commitments, the execution risk remains high when the company continues to report zero operating revenue and ongoing losses.

The company has itself identified primary risks as the inability to generate operational revenue, continued net losses, and the need to successfully execute the strategic initiatives under the resolution plan for capex and working capital. The qualified auditor conclusion on going concern, despite negative net worth, adds another layer of scrutiny for stakeholders.

Conclusion

Omkar Speciality Chemicals has moved out of CIRP following the NCLT’s July 31, 2025 approval, with the resolution framework setting out creditor payouts, debt reduction, and a full reset of share capital and ownership. But the FY26 Q1 to Q3 unaudited results show operations have not yet restarted meaningfully, with revenue from operations at ₹0 crore and continuing quarterly losses. The next confirmed milestones include monitoring committee actions, regulatory and stock exchange approvals, and execution of the record-date-driven cancellation and new equity issuance process.